In this context, the authors proposed that the use of glutaminase inhibitors alone or in combination with NRF2 inducers might be a valid therapeutic strategy to target different cancers respectively carrying functional or mutated forms of the KEAP1 gene [107]. Here, NFE2L2 is linked to cancer.